Eli Lilly's Once-Daily Oral Foundayo 17.2 Mg Outperforms Oral Semaglutide 25 Mg On Weight Loss, A1C At 52 Weeks In Type 2 Diabetes Indirect Comparison Presented At EASD Milan
Foundayo 17.2 mg was associated with 1.5% greater weight loss and 0.3% greater A1C reduction than oral semaglutide 25 mg at 52 weeksThese additional analyses build on findings of the ACHIEVE-3 head-to-head study, where
Eli Lilly's new diabetes pill beat a competitor's pill in weight loss and blood sugar control. When a company's medicine works better than others, people might want to use it more.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.